Gene expression profiling reveals novel targets of estramustine phosphate in prostate cancer cells

Cancer Letters

Volumn 209, Issue 2, 2004, Pages 187-195

  Hong, Xin ^a   Li, Yiwei ^a   Hussain, Maha ^b   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Estramustine phosphate; Gene expression; Microarray; Prostate cancer cells

Indexed keywords

ESTRAMUSTINE PHOSPHATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL CYCLE; CELL FUNCTION; CELL GROWTH; CLUSTER ANALYSIS; CONTROLLED STUDY; CYTOSKELETON; DNA MICROARRAY; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOMEOSTASIS; HUMAN; HUMAN CELL; IRON METABOLISM; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ESTRAMUSTINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 2442699985     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.02.008     Document Type: Article

References (43)

1. Tew K.D., Glusker J.P., Hartley-Asp B., Hudes G., Speicher L.A. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmacol. Ther. 56:1992;323-339
2. Seidman A.D., Scher H.I., Petrylak D., Dershaw D.D., Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol. 147:1992;931-934
3. Kreis W. Estramustine revisited. Cancer Treat. Res. 78:1995;163-184
4. Hudes G.R., Nathan F.E., Khater C., Greenberg R., Gomella L., Stern C., McAleer C. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin. Oncol. 22:1995;41-45
5. Hudes G.R., Greenberg R., Krigel R.L., Fox S., Scher R., Litwin S., et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J. Clin. Oncol. 10:1992;1754-1761
6. Tew K.D., Erickson L.C., White G., Wang A.L., Schein P.S., Hartley-Asp B. Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets. Mol. Pharmacol. 24:1983;324-328
7. Kruse E., Hartley-Asp B. The effect of estramustine, nor-nitrogen mustard and tauromustine on macromolecular labelling in the human prostatic tumour cell line 1013L. Pharmacol. Toxicol. 64:1989;9-13
8. Kreis W., Budman D.R., Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br. J. Urol. 79:1997;196-202
9. Hartley-Asp B. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3. Prostate. 5:1984;93-100
10. Hansenson M., Lundh B., Hartley-Asp B., Pousette A. Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r. Urol. Res. 16:1988;357-361
11. Tew K.D. The mechanism of action of estramustine. Semin. Oncol. 10:1983;21-26
12. Hartley-Asp B., Gunnarsson P.O. Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145). J. Urol. 127:1982;818-822
13. Dahllof B., Billstrom A., Cabral F., Hartley-Asp B. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53:1993;4573-4581
14. Von Schoultz E., Grankvist K., Gustavsson H., Henriksson R. Effects of estramustine on DNA and cell membrane in malignant glioma cells. Acta Oncol. 30:1991;719-723
15. Sandstrom P.E., Jonsson O., Grankvist K., Henriksson R. Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma and pulmonary carcinoma cell lines. Eur. J. Cancer. 30A:1994;1822-1826
16. Henriksson R., Bjermer L., Von Schoultz E., Grankvist K. The effect of estramustine on microtubuli is different from the direct action via oxygen radicals on DNA and cell membrane. Anticancer Res. 10:1990;303-309
17. Engstrom K.G., Grankvist K., Henriksson R. Early morphological detection of estramustine cytotoxicity measured as alteration in cell size and shape by a new technique of microperifusion. Eur. J. Cancer. 27:1991;1288-1295
18. Howe H.L., Wingo P.A., Thun M.J., Ries L.A., Rosenberg H.M., Feigal E.G., Edwards B.K. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl Cancer Inst. 93:2001;824-842
19. Brown P.O., Botstein D. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21:1999;33-37
20. Khatri P., Draghici S., Ostermeier G.C., Krawetz S.A. Profiling gene expression using onto-express. Genomics. 79:2002;266-270
21. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:2001;402-408
22. Tamayo P., Slonim D., Mesirov J., Zhu Q., Kitareewan S., Dmitrovsky E., et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc. Natl Acad. Sci. USA. 96:1999;2907-2912
23. Han H., Bearss D.J., Browne L.W., Calaluce R., Nagle R.B., Von Hoff D.D. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62:2002;2890-2896
24. Takemasa I., Higuchi H., Yamamoto H., Sekimoto M., Tomita N., Nakamori S., et al. Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. Biochem. Biophys. Res. Commun. 285:2001;1244-1249
25. Xie W., Mertens J.C., Reiss D.J., Rimm D.L., Camp R.L., Haffty B.G., Reiss M. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 62:2002;497-505
26. Xu J., Stolk J.A., Zhang X., Silva S.J., Houghton R.L., Matsumura M., et al. Identification of differentially expressed genes in human prostate cancer using subtraction and microarray. Cancer Res. 60:2000;1677-1682
27. Kudoh K., Ramanna M., Ravatn R., Elkahloun A.G., Bittner M.L., Meltzer P.S., et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60:2000;4161-4166
28. Zembutsu H., Ohnishi Y., Tsunoda T., Furukawa Y., Katagiri T., Ueyama Y., et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62:2002;518-527
29. Hussain M., Smith D.C., El Rayes B.F., Du W., Vaishampayan U., Fontana J., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology. 61:2003;774-780
30. Behnam-Motlagh P., Jonsson O., Engstrom K.G., Henriksson R., Grankvist K. Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion. Br. J. Cancer. 76:1997;318-324
31. Sandstrom P.E., Jonsson O., Grankvist K., Henriksson R. Identification of potassium flux pathways and their role in the cytotoxicity of estramustine in human malignant glioma, prostatic carcinoma and pulmonary carcinoma cell lines. Eur. J. Cancer. 30A:1994;1822-1826
32. Marklund L., Henriksson R., Grankvist K. Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide. Int. J. Cancer. 93:2001;577-583
33. Fernandez-Sarabia M.J., Bischoff J.R. Bcl-2 associates with the ras-related protein R-ras p23. Nature. 366:1993;274-275
34. Correia J.J. Effects of antimitotic agents on tubulin-nucleotide interactions. Pharmacol. Ther. 52:1991;127-147
35. Hollander M.C., Zhan Q., Bae I., Fornace A.J. Jr. Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J. Biol. Chem. 272:1997;13731-13737
36. Hollander M.C., Sheikh M.S., Yu K., Zhan Q., Iglesias M., Woodworth C., Fornace A.J. Jr. Activation of Gadd34 by diverse apoptotic signals and suppression of its growth inhibitory effects by apoptotic inhibitors. Int. J. Cancer. 96:2001;22-31
37. Novoa I., Zeng H., Harding H.P., Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J. Cell Biol. 153:2001;1011-1022
38. Derynck R., Akhurst R.J., Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat. Genet. 29:2001;117-129
39. Wakefield L.M., Roberts A.B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12:2002;22-29
40. Payton M., Coats S. Cyclin E2, the cycle continues. Int. J. Biochem. Cell Biol. 34:2002;315-320
41. Gasparotto D., Maestro R., Piccinin S., Vukosavljevic T., Barzan L., Sulfaro S., Boiocchi M. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 57:1997;2366-2368
42. Grana X., Reddy E.P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:1995;211-219
43. Horne M.C., Donaldson K.L., Goolsby G.L., Tran D., Mulheisen M., Hell J.W., Wahl A.F. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J. Biol. Chem. 272:1997;12650-12661